World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF THYROID CANCER USING SIMILAR MOLECULE - N-DESETHYL SUNITINIB

Nazneen*, Dr. Syed Ahmed Hussain, Faheem Unnisa, Arshiya Tarannum, Umaima Batool Osmani, Raheem Unnisa Shaik and Maimuna Fatima

ABSTRACT

Aim: To evaluate the anticancer potential of N-Desethyl Sunitinib as an alternative to the marketed drug
Lenvatinib in thyroid cancer treatment. Objective: The study aims to assess and compare the cytotoxic effects of
N-Desethyl Sunitinib on thyroid cancer cell lines using five different cell viability and cytotoxicity assays.
Research: The study utilized in vitro assays, including MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH, to
measure the cell viability and cytotoxicity of N-Desethyl Sunitinib in thyroid cancer cells. Results were compared
to Lenvatinib, the standard therapeutic agent. N-Desethyl Sunitinib demonstrated a dose-dependent decrease in cell
viability across all assays, with significant cytotoxic effects observed at higher concentrations. Conclusion: NDesethyl
Sunitinib shows potent anticancer activity against thyroid cancer cell lines, reducing cell viability and
causing cytotoxicity in a dose-dependent manner. These findings suggest that it could be a viable alternative to
Lenvatinib for thyroid cancer therapy, warranting further investigation.

[Full Text Article]   [Download Certificate]